Gynecologic oncology
Audio Summaries

Diagnostic value of FAM19A4/SOX1/PAX1 methylation in non-16/18 high-risk HPV cervical lesions

Jun 23, 2026

The authors aimed to evaluate the diagnostic performance of FAM19A4, SOX1, and PAX1 methylation testing as a triage method for women aged 30 and older with positive non-16/18 high-risk HPV. Their findings indicate that this methylation testing not only correlates with the severity of cervical intraepithelial neoplasia (CIN) but also offers higher specificity and comparable sensitivity compared to traditional cytology, potentially reducing unnecessary colposcopy referrals and improving management strategies for these patients.

Occult invasive and preneoplastic lesions at risk-reducing salpingo-oophorectomy in BRCA1/2 carriers: A multicenter retrospective cohort study

Jun 19, 2026

The study aimed to evaluate the prevalence and types of occult invasive or preneoplastic lesions found in BRCA1/2 carriers undergoing risk-reducing salpingo-oophorectomy (RRSO). The findings revealed that approximately 10% of the women had occult invasive or microinvasive malignancies, with BRCA1 c.5266dupC being the most common recurrent variant among the cohort.

Could chemotherapy response score act as a surrogate marker of response to PARP inhibitor maintenance treatment in patients with advanced ovarian cancer?

Jun 15, 2026

The authors aimed to determine if the Chemotherapy Response Score (CRS) could serve as a surrogate marker for predicting the benefit of PARP inhibitor maintenance treatment in patients with advanced ovarian cancer. Their findings indicate that patients with a higher CRS (2-3) experienced improved progression-free survival (PFS) with PARP inhibitor maintenance, while those with a lower CRS (1) did not show any survival benefit. This suggests that CRS may be a useful tool for guiding treatment decisions, especially in cases where genetic testing is not readily available.

Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes

Jun 15, 2026

The authors aimed to evaluate the impact of a structured multimodal prehabilitation program during neoadjuvant chemotherapy (NACT) on chemotherapy delivery, treatment tolerability, and surgical candidacy in patients with advanced-stage ovarian cancer. Their findings indicate that prehabilitation is associated with improved relative dose intensity of chemotherapy and a lower failure rate to proceed to interval debulking surgery, particularly in patients aged 70 and older. These results suggest that prehabilitation may enhance treatment adherence and outcomes in advanced ovarian cancer.

Cardiovascular outcomes in individuals with ovarian cancer: A retrospective cohort study

Jun 13, 2026

This study aims to investigate the association between ovarian cancer and the subsequent risk of cardiovascular disease (CVD) in female patients. The findings reveal that ovarian cancer patients have a higher incidence of major adverse cardiovascular events compared to matched non-cancer controls, with a particularly pronounced risk in those under 55 years of age. The authors suggest the need for further research to understand the underlying mechanisms linking ovarian cancer and increased CVD risk.

Opportunistic salpingectomy during non-gynecologic surgery: Canadian surgeons' experience, barriers and facilitators

Jun 13, 2026

The authors aimed to assess the experiences, barriers, and facilitators related to the adoption of opportunistic salpingectomy among Canadian general and urologic surgeons during non-gynecologic surgeries, given its potential to reduce ovarian cancer risk. The study found that while a majority of surgeons expressed motivation to perform the procedure, many were unaware of existing recommendations, and significant barriers included patient consent issues and reimbursement challenges. The authors suggest that enhanced training and resources could improve the procedure's uptake and ultimately decrease ovarian cancer incidence.

Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study

Jun 12, 2026

The AdORN study aimed to evaluate the safety and efficacy of atezolizumab, an immune checkpoint inhibitor, in combination with neoadjuvant chemotherapy for patients with newly diagnosed advanced-stage epithelial ovarian cancer. The results indicated that the treatment was feasible, did not delay interval cytoreductive surgery, and showed promising response rates, with notable changes in immune markers associated with treatment response. However, the study faced early termination due to negative results from a related trial, limiting patient enrollment and further analysis.

Raising the bar on surgical site infection bundles: Preoperative penicillin allergy testing in gynecologic oncology patients with a reported penicillin allergy - A quality improvement study

Jun 12, 2026

The authors aimed to determine whether implementing preoperative penicillin allergy testing (PAT) could increase the use of cefazolin for surgical site infection (SSI) prophylaxis in gynecologic oncology patients with reported penicillin allergies. Their quality improvement study showed a significant increase in cefazolin use from 42% to 77.3% post-intervention, with a subsequent reduction in SSI rates to 0%. The findings suggest that routine PAT can enhance antibiotic stewardship and reduce the risk of SSIs in this patient population.

Referral patterns for genetic counseling and completion of germline testing in patients younger than 50 years with endometrial cancer

Jun 11, 2026

The authors aimed to characterize referral patterns and identify factors influencing genetic evaluation in patients under 50 years old diagnosed with endometrial cancer. They found that only 60% of eligible patients were referred for genetic counseling, with geographic location affecting referral likelihood, while advanced disease stages decreased referral chances. The study highlights a significant gap in guideline-concordant care and underscores the need for systemic improvements to enhance access to genetic services, given the 12.5% mutation detection rate among those tested.

Pelvic exenteration for cervical cancer - Oncologic outcome and long-term health-related quality of life, a mixed methods study

Jun 9, 2026

This study investigates the long-term oncologic outcomes and health-related quality of life (HRQoL) for patients undergoing pelvic exenteration (PE) due to recurrent cervical cancer. The findings reveal that while PE can provide significant survival benefits, patients experience persistent physical and psychosocial challenges, highlighting the need for tailored support and follow-up care. The authors emphasize the importance of understanding both quantitative and qualitative aspects of survivorship to improve patient outcomes.